Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.76 |
| ▸ | INSR | P06213 | 12/20 | 0.76 |
| ▸ | NPM1 | P06748 | 10/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17703361 | 1.00 | ALK (0.76) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL1545746 | 0.93 | ALK (0.77) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL1545581 | 0.93 | ALK (0.83) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL17703363 | 0.91 | ALK (0.84) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL1546320 | 0.91 | ALK (0.84) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL17703344 | 0.89 | ALK (0.67) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL12245803 | 0.87 | ALK (0.57) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL12213956 | 0.87 | ALK (1.00) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL1546156 | 0.86 | ALK (0.85) | ALKINSRNPM1CYP3A4KCNH2 | |
| SCHEMBL1546097 | 0.86 | ALK (0.85) | ALKINSRNPM1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | claimed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | claimed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | claimed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-3012249-A1 | COMPOUNDS AND COMPOSITION AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| EP-2311807-B1 | Compounds and composition as protein kinase inhibitors | NOVARTIS AG (CH) | 2015-11-11 | — | — | EP | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-04-16 | — | — | US | disclosed |
| US-8957081-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2015-02-17 | — | — | US | disclosed |
| US-8039479-B2 | Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor | IRM LLC (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039479-B2 | Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor | IRM LLC (BM) | 2011-10-18 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| EP-2311807-A1 | Compounds and composition as protein kinase inhibitors | IRM LLC (BM) | 2011-04-20 | — | — | EP | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008073687-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
| US-20150105390-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALK 23/4885INSR 67/4885NPM1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.